NASDAQ:DSGN Design Therapeutics Q3 2025 Earnings Report $6.62 +0.13 (+2.00%) Closing price 04:00 PM EasternExtended Trading$6.62 0.00 (0.00%) As of 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Design Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.34Beat/MissN/AOne Year Ago EPSN/ADesign Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ADesign Therapeutics Announcement DetailsQuarterQ3 2025Date11/6/2025TimeBefore Market OpensConference Call DateFriday, November 7, 2025Conference Call Time4:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Design Therapeutics Earnings HeadlinesDesign Therapeutics Appoints Justin Gover to Board of DirectorsSeptember 10, 2025 | globenewswire.comDesign Therapeutics, Inc. (DSGN) Presents at Cantor Global Healthcare Conference 2025 TranscriptSeptember 5, 2025 | seekingalpha.comREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for yourself. Once you see what’s unfolding behind the scenes, you’ll understand why I rushed this interview and opportunity to you today.October 14 at 2:00 AM | Paradigm Press (Ad)Design Therapeutics to Participate in the 2025 Cantor Global Healthcare ConferenceAugust 27, 2025 | globenewswire.comDesign Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial ResultsAugust 7, 2025 | globenewswire.comDesign Therapeutics Inc (DSGN) - Investing.comJuly 10, 2025 | investing.comSee More Design Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Design Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Design Therapeutics and other key companies, straight to your email. Email Address About Design TherapeuticsDesign Therapeutics (NASDAQ:DSGN) a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.View Design Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Congress Is Buying Intuitive Surgical Ahead of Earnings3 Reasons to Buy Sprouts Farmers Market Ahead of EarningsTesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff Concerns Upcoming Earnings ASML (10/15/2025)Abbott Laboratories (10/15/2025)Bank of America (10/15/2025)Kinder Morgan (10/15/2025)Morgan Stanley (10/15/2025)Progressive (10/15/2025)Prologis (10/15/2025)The PNC Financial Services Group (10/15/2025)CSX (10/16/2025)Interactive Brokers Group (10/16/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
